论文部分内容阅读
目的:观察替吉奥联合奥沙利铂治疗进展期胃癌的疗效,探讨其对癌组织中基质金属蛋白酶-9(MMP-9)表达的影响。方法:120例进展期胃癌患者随机分为观察组和对照组,每组60例,均接受新辅助化疗方案治疗3个周期:观察组给予替吉奥胶囊联合奥沙利铂;对照组给予氟尿嘧啶联合奥沙利铂化疗。观察两组近期疗效、不良反应及化疗前后癌组织中MMP-9表达的变化。结果:治疗后,观察组和对照组客观缓解率差异无统计学意义(P>0.05),观察组临床受益率显著高于对照组(P<0.01);观察组重度骨髓抑制和肝肾功能损害发生率明显低于对照组(P<0.05);观察组MMP-9的阳性表达率明显低于对照组(P<0.05)。结论:替吉奥胶囊联合奥沙利铂可提高进展期胃癌患者的临床受益率,且能有效降低癌组织中MMP-9的表达。
OBJECTIVE: To observe the curative effect of TEGO combined with oxaliplatin in the treatment of advanced gastric cancer and to explore its effect on the expression of matrix metalloproteinase-9 (MMP-9) in cancer tissue. Methods: A total of 120 patients with advanced gastric cancer were randomly divided into observation group and control group, 60 cases in each group, receiving neoadjuvant chemotherapy regimen for 3 cycles: the observation group was treated with tioguan capsule plus oxaliplatin; the control group was given fluorouracil Combined oxaliplatin chemotherapy. The curative effect, adverse reactions and the changes of MMP-9 expression in cancer tissues before and after chemotherapy were observed. Results: After treatment, there was no significant difference in the objective response rate between the observation group and the control group (P> 0.05), and the clinical benefit rate in the observation group was significantly higher than that in the control group (P <0.01). Severe myelosuppression and hepatic and renal dysfunction (P <0.05). The positive expression rate of MMP-9 in the observation group was significantly lower than that in the control group (P <0.05). CONCLUSION: The combination of TIGO capsules and oxaliplatin can improve the clinical benefit rate of patients with advanced gastric cancer and can effectively reduce the expression of MMP-9 in cancer tissues.